Global oncology biosimilars market 2014-2018

The global oncology biosimilars market is expected to expand at a compound annual growth rate (CAGR) of 29.87% over the period 2013-2018, according to a new report added to the offering of Research and Markets.

Biosimilar medicines have a mechanism of action that is similar to that of the original biological medicines. Though biosimilars have many similarities to the innovator product, they are not an exact copy of the reference biopharmaceutical product. Currently, biosimilars are being incorporated into oncology treatment practices. The biosimilars used in oncology in the supportive care setting are known as oncology biosimilars.

The development and introduction of biosimilars, according to the report, will be dominated by India’s Biocon and Dr Reddy’s, South Korea’s Celltrion, US firms Hospira and Mylan, and Sandoz, the generics subsidiary of Swiss drug major Novartis.